Diagnostic significance of peritumoral enhancement in distinguishing between muscle-invasive and non-muscle-invasive bladder cancer

被引:0
|
作者
Takeuchi, Mitsuru [1 ,2 ]
Higaki, Atsushi [2 ]
Kojima, Yuichi [2 ]
Ono, Kentaro [2 ]
Maruhisa, Takuma [2 ]
Yokoyama, Takatoshi [2 ]
Watanabe, Hiroyuki [2 ]
Yamamoto, Akira [2 ]
Tamada, Tsutomu [2 ]
机构
[1] Radiolonet Tokai, Nagoya, Japan
[2] Kawasaki Med Sch, Kurashiki, Japan
关键词
Urinary bladder neoplasms; Multiparametric magnetic resonance imaging; peritumoral enhancement; VI-RADS; Dynamic contrast-enhanced imaging; ENDOMETRIAL CANCER; ACCURACY; MRI;
D O I
10.1007/s00261-024-04658-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective The aim of this study was to assess the prevalence of peritumoral enhancement (PTE) in patients with muscle-invasive bladder cancer (MIBC) and non-MIBC (NMIBC) and to propose a modified diagnostic criterion for Vesical Imaging Reporting and Data System (VI-RADS) that incorporates PTE. Materials and methods This retrospective study included 95 patients with bladder cancer (age, 72 +/- 11; 77 men; 36 MIBCs and 59 Non-MIBCs) who underwent multiparametric MRI in our referral center between 2011 and 2023. The images were interpreted by four radiologists. The readers classified the possibility of muscle layer invasion into categories 1-5, based on the VI-RADS categorical diagnostic criterion. PTE was defined as a linear contrast enhancement observed at the edge of tumor invasion which is convex outward from the normal bladder wall and contrasts more than the normal muscle layer and tumor. A modified VI-RADS that upgrades the final VI-RADS category to 4 if PTE is present when the original VI-RADS category is 3 or less was proposed. The frequency of PTE in the MIBC and NMIBC groups was compared using the Fisher's exact test. Sensitivity and specificity for the diagnosis of MIBC were compared with the original VI-RADS using McNemar test. Pathologic diagnosis was used as the reference standard. Results PTE was present in 70-81% (25/36-29/36) of MIBC and absent in 92-98% (54/59-58/59) of non-MIBC. For all readers, the PTE was significantly more frequent (p < 0.001) in the MIBC group than the NMIBC group. The sensitivities of modified VI-RADS (75.0-86.1%) were significantly higher than those of original VI-RADS (41.7-55.6%) (p = 0.002-0.008). The specificity of modified VI-RADS (91.5-98.3%) were not statistically different from original VI-RADS (98.3-100%). Conclusions In conclusion, PTE is a highly specific finding for MIBC. modified VI-RADS incorporating PTE increases sensitivity for MIBC.
引用
收藏
页码:1679 / 1688
页数:10
相关论文
共 50 条
  • [41] Mutational landscape of non-muscle-invasive bladder cancer
    Hurst, Carolyn D.
    Knowles, Margaret A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (07) : 295 - 303
  • [42] Current management of non-muscle-invasive bladder cancer
    Rodriguez Faba, O.
    Gaya, J. M.
    Lopez, J. M.
    Capell, M.
    De Gracia-Nieto, A. E.
    Gomez Correa, E.
    Breda, A.
    Palou, J.
    MINERVA MEDICA, 2013, 104 (03) : 273 - 286
  • [43] Intravesical chemotherapy in non-muscle-invasive bladder cancer
    Porten, Sima P.
    Leapman, Michael S.
    Greene, Kirsten L.
    INDIAN JOURNAL OF UROLOGY, 2015, 31 (04) : 297 - 303
  • [44] Guideline of guidelines: non-muscle-invasive bladder cancer
    Woldu, Solomon L.
    Bagrodia, Aditya
    Lotan, Yair
    BJU INTERNATIONAL, 2017, 119 (03) : 371 - 380
  • [45] New therapies for non-muscle-invasive bladder cancer
    Chiong, Edmund
    Esuvaranathan, Kesavan
    WORLD JOURNAL OF UROLOGY, 2010, 28 (01) : 71 - 78
  • [46] Review of current optical diagnostic techniques for non-muscle-invasive bladder cancer
    Kolodziej, Anna
    Krajewski, Wojciech
    Matuszewski, Michal
    Tupikowski, Krzysztof
    CENTRAL EUROPEAN JOURNAL OF UROLOGY, 2016, 69 (02) : 150 - 156
  • [47] FLUORESCENT CYSTOSCOPY WITH HEXAMINOLEVULINATE: DIAGNOSTIC ACCURACY FOR NON-MUSCLE-INVASIVE BLADDER CANCER
    Volpe, Alessandro
    Giraudo, Davide
    Billia, Michele
    Sogni, Filippo
    Varvello, Francesco
    Zacchero, Monica
    Terrone, Carlo
    ANTICANCER RESEARCH, 2011, 31 (05) : 1904 - 1904
  • [48] Chemotherapy for Muscle-Invasive Bladder Cancer
    Patrizia Trenta
    Fabio Calabrò
    Linda Cerbone
    Cora N. Sternberg
    Current Treatment Options in Oncology, 2016, 17
  • [49] The management of muscle-invasive bladder cancer
    Albertsen, Peter C.
    BJU INTERNATIONAL, 2021, 128 (03) : 290 - +
  • [50] Management of muscle-invasive bladder cancer
    Moon, Andrew
    Van der Voet, Hans
    Cresswell, Jo
    TRENDS IN UROLOGY & MENS HEALTH, 2015, 6 (06) : 7 - 11